181 related articles for article (PubMed ID: 31698111)
1. Changes in Dosing and Dose Timing of D-Cycloserine Explain Its Apparent Declining Efficacy for Augmenting Exposure Therapy for Anxiety-related Disorders: An Individual Participant-data Meta-analysis.
Rosenfield D; Smits JAJ; Hofmann SG; Mataix-Cols D; de la Cruz LF; Andersson E; Rück C; Monzani B; Pérez-Vigil A; Frumento P; Davis M; de Kleine RA; Difede J; Dunlop BW; Farrell LJ; Geller D; Gerardi M; Guastella AJ; Hendriks GJ; Kushner MG; Lee FS; Lenze EJ; Levinson CA; McConnell H; Plag J; Pollack MH; Ressler KJ; Rodebaugh TL; Rothbaum BO; Storch EA; Ströhle A; Tart CD; Tolin DF; van Minnen A; Waters AM; Weems CF; Wilhelm S; Wyka K; Altemus M; Anderson P; Cukor J; Finck C; Geffken GR; Golfels F; Goodman WK; Gutner CA; Heyman I; Jovanovic T; Lewin AB; McNamara JP; Murphy TK; Norrholm S; Thuras P; Turner C; Otto MW
J Anxiety Disord; 2019 Dec; 68():102149. PubMed ID: 31698111
[TBL] [Abstract][Full Text] [Related]
2. D-Cycloserine Augmentation of Exposure-Based Cognitive Behavior Therapy for Anxiety, Obsessive-Compulsive, and Posttraumatic Stress Disorders: A Systematic Review and Meta-analysis of Individual Participant Data.
Mataix-Cols D; Fernández de la Cruz L; Monzani B; Rosenfield D; Andersson E; Pérez-Vigil A; Frumento P; de Kleine RA; Difede J; Dunlop BW; Farrell LJ; Geller D; Gerardi M; Guastella AJ; Hofmann SG; Hendriks GJ; Kushner MG; Lee FS; Lenze EJ; Levinson CA; McConnell H; Otto MW; Plag J; Pollack MH; Ressler KJ; Rodebaugh TL; Rothbaum BO; Scheeringa MS; Siewert-Siegmund A; Smits JAJ; Storch EA; Ströhle A; Tart CD; Tolin DF; van Minnen A; Waters AM; Weems CF; Wilhelm S; Wyka K; Davis M; Rück C; ; Altemus M; Anderson P; Cukor J; Finck C; Geffken GR; Golfels F; Goodman WK; Gutner C; Heyman I; Jovanovic T; Lewin AB; McNamara JP; Murphy TK; Norrholm S; Thuras P
JAMA Psychiatry; 2017 May; 74(5):501-510. PubMed ID: 28122091
[TBL] [Abstract][Full Text] [Related]
3. Dose Timing of D-Cycloserine to Augment Exposure Therapy for Social Anxiety Disorder: A Randomized Clinical Trial.
Smits JAJ; Pollack MH; Rosenfield D; Otto MW; Dowd S; Carpenter J; Dutcher CD; Lewis EM; Witcraft SM; Papini S; Curtiss J; Andrews L; Kind S; Conroy K; Hofmann SG
JAMA Netw Open; 2020 Jun; 3(6):e206777. PubMed ID: 32496566
[TBL] [Abstract][Full Text] [Related]
4. A Meta-Analysis of D-Cycloserine in Exposure-Based Treatment: Moderators of Treatment Efficacy, Response, and Diagnostic Remission.
McGuire JF; Wu MS; Piacentini J; McCracken JT; Storch EA
J Clin Psychiatry; 2017 Feb; 78(2):196-206. PubMed ID: 27314661
[TBL] [Abstract][Full Text] [Related]
5. A meta-analysis of D-cycloserine and the facilitation of fear extinction and exposure therapy.
Norberg MM; Krystal JH; Tolin DF
Biol Psychiatry; 2008 Jun; 63(12):1118-26. PubMed ID: 18313643
[TBL] [Abstract][Full Text] [Related]
6. Dose timing of D-cycloserine to augment cognitive behavioral therapy for social anxiety: Study design and rationale.
Hofmann SG; Carpenter JK; Otto MW; Rosenfield D; Smits JA; Pollack MH
Contemp Clin Trials; 2015 Jul; 43():223-30. PubMed ID: 26111923
[TBL] [Abstract][Full Text] [Related]
7. Extinction learning as a moderator of d-cycloserine efficacy for enhancing exposure therapy in posttraumatic stress disorder.
de Kleine RA; Smits JA; Hendriks GJ; Becker ES; van Minnen A
J Anxiety Disord; 2015 Aug; 34():63-7. PubMed ID: 26121495
[TBL] [Abstract][Full Text] [Related]
8. Augmentation of exposure therapy with post-session administration of D-cycloserine.
Tart CD; Handelsman PR; Deboer LB; Rosenfield D; Pollack MH; Hofmann SG; Powers MB; Otto MW; Smits JA
J Psychiatr Res; 2013 Feb; 47(2):168-74. PubMed ID: 23098672
[TBL] [Abstract][Full Text] [Related]
9. D-cycloserine enhancement of exposure therapy for social anxiety disorder depends on the success of exposure sessions.
Smits JA; Rosenfield D; Otto MW; Marques L; Davis ML; Meuret AE; Simon NM; Pollack MH; Hofmann SG
J Psychiatr Res; 2013 Oct; 47(10):1455-61. PubMed ID: 23870811
[TBL] [Abstract][Full Text] [Related]
10. Effect of D-Cycloserine on the Effect of Concentrated Exposure and Response Prevention in Difficult-to-Treat Obsessive-Compulsive Disorder: A Randomized Clinical Trial.
Kvale G; Hansen B; Hagen K; Abramowitz JS; Børtveit T; Craske MG; Franklin ME; Haseth S; Himle JA; Hystad S; Kristensen UB; Launes G; Lund A; Solem S; Öst LG
JAMA Netw Open; 2020 Aug; 3(8):e2013249. PubMed ID: 32789516
[TBL] [Abstract][Full Text] [Related]
11. D-cycloserine-augmented one-session treatment of specific phobias in children and adolescents.
Farrell LJ; Waters AM; Oar EL; Tiralongo E; Garbharran V; Alston-Knox C; McConnell H; Collings N; Zimmer-Gembeck M; Donovan CL; Testa C; Storch EA; Ollendick TH
Brain Behav; 2018 Jun; 8(6):e00984. PubMed ID: 30106248
[TBL] [Abstract][Full Text] [Related]
12. Enhancement of Psychosocial Treatment With D-Cycloserine: Models, Moderators, and Future Directions.
Otto MW; Kredlow MA; Smits JAJ; Hofmann SG; Tolin DF; de Kleine RA; van Minnen A; Evins AE; Pollack MH
Biol Psychiatry; 2016 Aug; 80(4):274-283. PubMed ID: 26520240
[TBL] [Abstract][Full Text] [Related]
13. D-cycloserine augmentation of cognitive behavioral therapy for anxiety disorders: an update.
Hofmann SG; Otto MW; Pollack MH; Smits JA
Curr Psychiatry Rep; 2015 Jan; 17(1):532. PubMed ID: 25413638
[TBL] [Abstract][Full Text] [Related]
14. A placebo-controlled randomized trial of D-cycloserine augmentation of cue exposure therapy for smoking cessation.
Otto MW; Pachas GN; Cather C; Hoeppner SS; Moshier SJ; Hearon BA; Ward HB; Laffer AB; Smits JAJ; Evins AE
Cogn Behav Ther; 2019 Jan; 48(1):65-76. PubMed ID: 30111253
[TBL] [Abstract][Full Text] [Related]
15. D-cycloserine as an augmentation strategy for cognitive behavioral therapy for anxiety disorders: an update.
Hofmann SG; Sawyer AT; Asnaani A
Curr Pharm Des; 2012; 18(35):5659-62. PubMed ID: 22632472
[TBL] [Abstract][Full Text] [Related]
16. Difficult-to-treat pediatric obsessive-compulsive disorder: feasibility and preliminary results of a randomized pilot trial of D-cycloserine-augmented behavior therapy.
Farrell LJ; Waters AM; Boschen MJ; Hattingh L; McConnell H; Milliner EL; Collings N; Zimmer-Gembeck M; Shelton D; Ollendick TH; Testa C; Storch EA
Depress Anxiety; 2013 Aug; 30(8):723-31. PubMed ID: 23722990
[TBL] [Abstract][Full Text] [Related]
17. d-Cycloserine does not enhance the effects of in vivo exposure among young people with broad-based anxiety disorders.
Rapee RM; Jones MP; Hudson JL; Malhi GS; Lyneham HJ; Schneider SC
Behav Res Ther; 2016 Dec; 87():225-231. PubMed ID: 27771572
[TBL] [Abstract][Full Text] [Related]
18. No Effects of D-Cycloserine Enhancement in Exposure With Response Prevention Therapy in Panic Disorder With Agoraphobia: A Double-Blind, Randomized Controlled Trial.
Hofmeijer-Sevink MK; Duits P; Rijkeboer MM; Hoogendoorn AW; van Megen HJ; Vulink NC; Denys DA; van den Hout MA; van Balkom AJ; Cath DC
J Clin Psychopharmacol; 2017 Oct; 37(5):531-539. PubMed ID: 28820746
[TBL] [Abstract][Full Text] [Related]
19. D-cycloserine augmentation of behavioral therapy for the treatment of anxiety disorders: a meta-analysis.
Bontempo A; Panza KE; Bloch MH
J Clin Psychiatry; 2012 Apr; 73(4):533-7. PubMed ID: 22579153
[TBL] [Abstract][Full Text] [Related]
20. D-cycloserine augmentation of behavior therapy for anxiety and obsessive-compulsive disorders: A meta-analysis.
Bürkner PC; Bittner N; Holling H; Buhlmann U
PLoS One; 2017; 12(3):e0173660. PubMed ID: 28282427
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
